Contracts Worth 5.3 Billion Won Signed

CGBio, a company specializing in bio-regenerative medicine, announced on March 27 that it participated in the 41st Korea International Medical & Hospital Equipment Show (KIMES 2026), held recently at COEX in Samseong-dong, Seoul, where it showcased products in the fields of aesthetic plastic surgery, wound care, bone and spine, and internal and external medicine. During the event, the company signed overseas supply contracts worth a total of 5.3 billion won with partners from five countries.

Yu Hyunseung, CEO of CS Bio, is introducing key product lines to overseas buyers at the KIMES 2026 event. CS Bio

Yu Hyunseung, CEO of CS Bio, is introducing key product lines to overseas buyers at the KIMES 2026 event. CS Bio

View original image

KIMES is a leading medical device and hospital equipment exhibition, bringing together healthcare professionals, industry insiders, and domestic and international buyers to explore the latest medical technologies and market trends. At this year’s exhibition, CGBio focused on presenting its competitiveness as an integrated solution provider by highlighting the synergy between its key product lines, rather than simply introducing individual products.


In particular, the company prominently displayed its core products, including FACETEM (aesthetic plastic surgery), Curasys ME (wound care), NOVOSIS (bone substitute), and CG GEL (endoscopic hemostatic agent).


FACETEM is a collagen stimulator that goes beyond a simple filler by inducing in-body collagen production, catering to the latest global aesthetic market trends that emphasize natural volume enhancement and skin regeneration. Curasys ME is a next-generation negative pressure wound therapy (NPWT) device, designed with user convenience for both healthcare professionals and patients in mind, providing a more efficient wound care environment. NOVOSIS, based on its superior bone formation capabilities, is CGBio’s flagship product demonstrating the company’s technological edge in the bone and spine sector. CG GEL is a hemostatic agent for endoscopic procedures, showcasing its applicability in surgery and treatment settings by controlling bleeding during such operations.


Additionally, CGBio exhibited a wide range of products across various fields, including AILEENE, GISELLELIGNE, LUXX, DOOTH, Curasys2, CuraVAC Double Channel, BELUNA, NOVOMAX, Verteon, EXCENDER, CUVIS-Spine, Solendos Endo Tower, Realist Bone Model, ARISTENT, and NOVONIX.


During the exhibition, CGBio strengthened its foundation for global market expansion by proposing customized strategies tailored to the medical environment and partner needs of each country. Through on-site consultations, the company explained the clinical value and potential applications of each product line, expanding its connections with overseas buyers.


Contract signing ceremonies with overseas partners were also held during the exhibition. CGBio signed exclusive supply agreements for FACETEM in Singapore and Malaysia with Neuva Era, and for FACETEM in Pakistan with MediNova Healthcare. The company also entered into a supply agreement for CGDerm One-Step with HCT Regenerative Co., Ltd., and signed a supply contract for wound care solutions—including Curasys, CuraVAC, EasyFoam, and Easydew MD Cream—with Variance Trading Corporation.



Yu Hyunseung, CEO of CGBio, stated, “KIMES 2026 was an opportunity for CGBio to demonstrate its competitiveness as a comprehensive medical device solutions company, moving beyond a focus on individual products, to the global market. We plan to continue expanding our overseas business base through strategic product proposals and partnerships tailored to the needs of each market and partner.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing